

Shareholders Update – 2021-Q2

Dear shareholders of Paragate Medical, herein is a brief quarterly update:

- **Product Development:** Completion of long term verification & validation activities for its initial product (IPUDx), which was submitted for first in human clinical trial in Poland and Israel.
- **HR:** Luciano Frattini, former president & CEO of Medtronic Italy has joined the Advisory board as director of strategy. With a 10-digit figure annual turnover and over 2500 employees, Mr. Frattini has also led the acquisition and integration of Bellco srl., a 500 employees' company, focusing on dialysis solutions, into Medtronic Renal Care.
- **Programs and awards:** Paragate has been nominated as the winner of the [MEDLIM](#) 2021 program by [Medtronic BRC](#) Bakken Research Center and [LIOF](#) (Limburg development investment fund). Paragate has been selected to the Haifa based [In-Ventech](#) growth program and was granted Paragate with significant cash grant and benefits
- **Funding:** During H1/2021 Paragate has raised more than \$800,000 in equity, mostly through the public stage of [Together](#) funding platform, with additional expected commitments. The use of pre-venture round's proceeds is mainly for execution of the clinical trial.

We would like to thank you for your ongoing support.

The foregoing is, to the best of our knowledge, true and accurate.

Nitai Hanani
CEO

Nizar Mishael
CFO